Supplementary Table 4-18 and R script for WGCNA

Supplementary Table 4. List of annotated probes that were significantly (p <0.05) upregulated with ≥2-fold changes in any B cell subset of pSS compared with those of HCs.Supplementary Table 5. List of probes that were significantly (p <0.05) upregulated with ≥2-fold changes in all B cell subpopulations compared with those of HCs.Supplementary Tables 6 and 7. List of probes in gene co-expression modules of pSS (Table 6) and HCs (Table 7). To quantify associations of individual genes with the disease activity score (EULAR Sjögren's Syndrome Disease Activity Index, ESSDAI), we defined Gene Significance (GS) as the absolute value of the correlation between each gene and ESSDAI. P.GS represents the p-value of GS. For each module, we defined a quantitative measure of module membership (MM) as the correlation between the module eigengene and the gene expression profile. P.MM means the p value of MM. This allowed us to quantify the similarities among all genes of every module.Supplementary Table 8. List of canonical pathways associated with gene co-expression modules of pSS.Supplementary Table 9. List of upstream regulators associated with gene co-expression modules of pSS.Supplementary Table 10. List of disease and functions associated with gene co-expression modules of pSS.Supplementary Table 11. List of canonical pathways associated with the identified gene co-expression modules of HCs.Supplementary Table 12. List of upstream regulators associated with gene co-expression modules of HCs.Supplementary Table 13. List of disease and functions associated with gene co-expression modules of HCs.Supplementary Table 14. List of canonical pathways specific to pSS.Supplementary Table 15. List of upstream regulators specific to pSS.Supplementary Table 16. List of disease and functions specific to pSS.Supplementary Table 17. The distribution of ESSDAI of patients with pSS.Supplementary Table 18. The detailed clinical information of patients with pSS.补充表4。相较于健康对照（Healthy Controls, HCs），原发性干燥综合征（primary Sjögren's Syndrome, pSS）任一B细胞亚群中表达显著上调（p<0.05）且变化倍数≥2倍的注释探针列表。 补充表5。相较于健康对照，原发性干燥综合征所有B细胞亚群中表达显著上调（p<0.05）且变化倍数≥2倍的探针列表。 补充表6与补充表7。分别为原发性干燥综合征与健康对照的基因共表达模块探针列表。 为量化单个基因与疾病活动评分——欧洲抗风湿病联盟干燥综合征疾病活动指数（EULAR Sjögren's Syndrome Disease Activity Index, ESSDAI）——的关联，我们将基因显著性（Gene Significance, GS）定义为每个基因与ESSDAI之间相关系数的绝对值。P.GS代表基因显著性的p值。针对每个共表达模块，我们将模块成员度（module membership, MM）定义为模块特征基因与基因表达谱之间的相关系数。P.MM代表模块成员度的p值。通过上述定义，我们可量化每个模块内所有基因间的相似性。 补充表8。与原发性干燥综合征基因共表达模块相关的经典通路列表。 补充表9。与原发性干燥综合征基因共表达模块相关的上游调控因子列表。 补充表10。与原发性干燥综合征基因共表达模块相关的疾病与功能列表。 补充表11。与健康对照已鉴定基因共表达模块相关的经典通路列表。 补充表12。与健康对照基因共表达模块相关的上游调控因子列表。 补充表13。与健康对照基因共表达模块相关的疾病与功能列表。 补充表14。原发性干燥综合征特异性经典通路列表。 补充表15。原发性干燥综合征特异性上游调控因子列表。 补充表16。原发性干燥综合征特异性疾病与功能列表。 补充表17。原发性干燥综合征患者ESSDAI评分分布情况。 补充表18。原发性干燥综合征患者详细临床信息列表。